Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dexcom’s CGM sensors may be tiny, but the disclosures behind them are anything but. Each annual report details sensor accuracy studies, reimbursement progress, and manufacturing scale that drive the company’s growth. If you have ever searched for the G7 margin breakout or the cost of disposable sensors, you know the data is buried deep inside SEC exhibits.
Stock Titan’s AI engine makes those details surface quickly. Our platform delivers Dexcom SEC filings explained simply and tags the passages investors care about—whether it is an 8-K announcing an FDA clearance or the footnote that spells out international revenue. Get instant alerts for Dexcom Form 4 insider transactions real-time and track every share purchase or sale by executives. For deeper diligence, compare the Dexcom quarterly earnings report 10-Q filing against the prior period with side-by-side AI summaries.
Here is what you can explore in one place:
- Dexcom annual report 10-K simplified – sensor unit economics, R&D spending, and risk factors distilled into plain English.
- Dexcom 8-K material events explained – from product recalls to strategic partnerships.
- Dexcom executive stock transactions Form 4 – pattern recognition on option exercises and sales.
- Dexcom proxy statement executive compensation – understand incentive structures tied to new product launches.
Whether you need a quick Dexcom earnings report filing analysis before the call or are understanding Dexcom SEC documents with AI for a full valuation model, Stock Titan provides comprehensive coverage and real-time updates. No more hunting through EDGAR—critical insights on Dexcom insider trading Form 4 transactions land in your dashboard the moment they post.
DexCom, Inc. director trade: A DexCom (DXCM) director reported selling 2,906 shares of common stock on 11/14/2025 at $59.05 per share. The transaction was executed by the Richard A. Collins Revocable Trust under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025, designed to allow orderly sales over time. Following this sale, the trust holds 35,088 DexCom shares indirectly for the reporting person, and the director also holds 5,074 unvested restricted stock units granted on May 8, 2025, which will vest on the earlier of one year from grant or DexCom’s 2026 annual meeting of stockholders.
DexCom (DXCM) director Bridgette P. Heller reported an open-market sale of 1,012 common shares at $58.07 on November 12, 2025, executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.
Following the transaction, she beneficially owns 27,031 shares directly, which include 5,046 unvested RSUs granted May 8, 2025 that vest on the earlier of the one-year anniversary or DexCom’s 2026 annual meeting.
DexCom (DXCM) reported insider purchases by its President & COO, Jacob Steven Leach. On 11/10/2025, he bought 15,700 shares at a weighted average price of $54.977 and 2,500 shares at a weighted average price of $55.4252, executed in multiple trades within disclosed price ranges.
Following these transactions, he directly beneficially owned 331,697 shares. That total includes 84,537 unvested restricted stock units scheduled to vest through March 2026–2028 as previously granted. In addition, 47,296 shares are indirectly held through the Gregg Family Grandchildren's Trust, for which his spouse serves as a trustee.
Dexcom (DXCM) insider activity: Director Richard A. Collins, through the Richard A. Collins Revocable Trust, sold 3,948 shares of common stock on 11/10/2025 at $55.17 per share, pursuant to a Rule 10b5-1 plan adopted on August 7, 2025.
Following the sale, 37,994 shares are beneficially owned indirectly by the Trust. In addition, 5,074 unvested RSUs granted on May 8, 2025 will vest on the earlier of the one-year grant anniversary or DexCom’s 2026 Annual Meeting of Stockholders.
Dexcom delivered strong Q3 2025 results, led by higher disposable sensor volumes. Revenue reached $1,209.3 million, up 22% year over year, with gross profit of $731.4 million and operating income of $242.5 million. Net income rose to $283.8 million, and diluted EPS was $0.70, compared to $0.34 a year ago.
Margins benefited from higher manufacturing volumes and lower legal expenses, partially offset by pricing headwinds and production inefficiencies. Other income improved on gains from equity investments. Operating cash flow was $659.9 million for the quarter, supporting a strong liquidity position; cash, cash equivalents and short‑term marketable securities totaled $3.32 billion at quarter end.
The company repurchased 2.4 million shares for $187.2 million under its $750 million authorization. U.S. revenue was $851.9 million (70% of total), with International at $357.4 million (30%). Dexcom noted a tax benefit from its Malaysia tax holiday. Convertible notes outstanding remained at $2.46 billion principal with low coupons, and no conversions were reported.
Dexcom, Inc. (DXCM) furnished an 8‑K to announce financial results for the quarter ended September 30, 2025. The results were released via a press release furnished as Exhibit 99.1.
The company stated that the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The submission also includes the Cover Page Interactive Data File (Inline XBRL).
Dexcom, Inc. (DXCM) reported that director Euan Ashley acquired 7,166 restricted stock units on 10/24/2025 via a Form 4 filing.
The RSU grant was recorded at a $0 price and is scheduled to vest in three equal annual installments from the grant date. Following this transaction, the reporting person beneficially owned 7,166 shares, held with direct ownership.
Dexcom, Inc. (DXCM) — Initial insider ownership filing. Director Euan Ashley filed a Form 3 reporting no securities beneficially owned as of 10/24/2025. The filing is made by one reporting person and marks the initial statement of holdings for this insider role. A Power of Attorney (Exhibit 24) authorized the signature by an attorney-in-fact.
Dexcom expanded its Board and added new expertise. On October 24, 2025, the Board increased its size to ten directors and appointed Dr. Euan Ashley as a director, effective immediately, with a term expiring at the 2026 annual meeting. He joins the Nominating and Governance Committee and the Technology Committee; Kyle Malady steps down from the Nominating Committee and remains Technology Committee chair.
The Board also approved increasing the Board to eleven directors effective January 1, 2026, and confirmed the previously announced appointment of Jacob S. Leach effective that date, contingent on continued service. Dr. Ashley was deemed an independent director and received an initial $500,000 RSU grant vesting over three years, and will be eligible for an annual $345,000 RSU grant around the 2026 annual meeting; non‑employee director awards accelerate upon a change in control.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
